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Abstract: The present review highlights our findings in the field of antitumor gold complexes bearing biologi-
cally relevant molecules, such as DNA-bases, amino acids or peptide derivatives. The results show that very 
active complexes are achieved with this sort of ligands in several cancer cells. In these compounds the gold 
center is bonded to these biological molecules mainly through a sulfur atom belonging to a cysteine moiety 
or to a thionicotinic moiety as result of the functionalization of the biological compounds, and additionally 
phosphines or N-heterocyclic carbenes are present as ancillary ligands. These robust compounds are stable 
in the biological media and can be transported to their targets without previous deactivation. The presence 
of these scaffolds represents a good approach to obtain complexes with improved biologically activity, better 
transport and biodistribution to cancer cells. Thioredoxin reductase (TrxR) has been shown as the main target 
for these complexes and in some cases, DNA interactions has been also observed.
Keywords: amino acids; antitumor compounds; Distinguished Women in Chemistry and Chemical Engineering; 
DNA-base derivatives; gold complexes; peptides.
 Introduction
The medicinal chemistry of gold compounds has been explored throughout the history from the earliest civi-
lizations. Gold has been used in the form of medicinal preparations or elixirs for different illness in coun-
tries like China, India, Egypt and later in Europe. The earliest therapeutic application of gold compounds 
dates from 2500 B.C. in China, where gold was used to treat furuncles, smallpox or skin ulcers and also was 
associated as a medicine to seek longevity [1]. Although gold medicines have historically been used for the 
treatment of a wide range of ailments, the use of gold in medicine with a more scientific basis began in the 
early 1920s when the gold compound K[Au(CN)2] was clinically tested for its in vitro bacteriostatic effect and 
employed by Robert Koch to kill mycobacteria, the bacteria that causes tuberculosis. Its toxicity in the treat-
ment of the tuberculosis made that other gold species were used with this purpose, such as gold(I) thiolate 
complexes [2].
In the early 1930s, Jacques Forestier introduced the same thiolate complexes for the treatment of rheuma-
toid arthritis, which at that time was believed to be related to tuberculosis. These compounds have been utilized 
for a long time as the drug of choice for the treatment of rheumatoid arthritis. However, the undesired side-
effects at high concentrations, mainly nephrotoxicity, gave rise to the search for less toxic gold compounds. 
Thus, a second generation of gold drugs evolved, Auranofin, [(tetra-O-acetyl-β-D-glucopyranosyl)-thio]
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(triethylphosphine)-gold(I) (Fig. 1), which can be orally administrated, was designed and approved for the 
therapy of rheumatoid arthritis in 1985 [3].
The research carried out by Rosenberg and co-workers in the 1960s led to the discovery of the activity of 
cisplatin as chemotherapeutic drug for cancer treatment [4]. This opened a new world of opportunities for 
metal compounds as potential anticancer drugs. This fact, together with the immunodepressive and anti-
inflammatory effects that some antitumor drugs produce, impulsed the research in the antitumor activity of 
auranofin and other related gold complexes. Nowadays, gold complexes have exhibited excellent antiprolif-
erative activity in several tumor cell lines [5–10] and Auranofin itself is on clinical trials for the treatment of 
leukaemia cancer [11]. Additionally, mechanistic studies have showed that the interaction of gold complexes 
with DNA is not as strong as that found for platinum drugs, suggesting different pathways for the cytotoxicity. 
These studies conducted to the observation that relevant gold–protein interactions could be the potential 
biological targets responsible for the cytotoxic effects of gold compounds. Gold has a great tendency to bind 
sulfur donor ligands and, consequently, most of the thiol containing enzymes could be potential targets 
that are, in addition, overexpressed in cancer cells, thus providing potential anticancer targets for gold 
complex therapy. Mitochondria and pathways of oxidative phosphorylation are among the primary intracel-
lular targets, being the inhibition of the seleno-enzyme thioredoxin reductase (TrxR), glutathione reductase, 
cathepsin cysteine proteases, deubiquitinases, cysteine proteases regulating the ubiquitin system or protein 
tyrosine phosphatases, the main responsible pathways for the cytotoxicity of gold compounds [12–14].
Stability of the gold compounds in the biological media is an important feature for the development 
of gold-based drugs, and for that reason complexes bearing strong ligand-metal bonds have been mainly 
chosen. Consequently, the archetypal sort of ligand which has been used to build biologically active gold 
compounds are thiolates [15], dithiocarbamates [16], phosphines or phospholes [17, 18], N-heterocyclic car-









































































Fig. 1: Gold complexes with antitumor activity [15–22].
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reported in the last decades with excellent activity (see some examples in Fig. 1). Another important fact, in 
addition to the activity, is drug distribution and selectivity and for this reason ligands bearing biologically 
relevant molecules have been used with the purpose to improve these important aspects.
This review aims to cover the contributions of our group in the synthesis of anticancer gold complexes 
using relevant biological ligands, including thiolate complexes derived from DNA bases, which could be 
denominated as Auranofin analogues, or with amino acids or peptides, which are key molecules with an 
important role in many biological processes and additionally are overexpressed in cancer cells which, conse-
quently, could increase the selectivity to target cancer cells.
 Gold complexes with thiolate-based biomolecules
Thiolate metal complexes have received a great interest in different areas of research and special remark 
deserves their application in bioinorganic chemistry, mainly because of their presence in very diverse metal-
loproteins and metalloenzymes [23, 24], and in medicine as structural models for bioinorganic metallodrugs 
[25] or the use of gold thiolates in the treatment of arthritis [26].
Those complexes containing the P–Au–S unit have played an important role in the development of gold 
drugs because their structural similarity to Auranofin. Many efforts have been devoted to the synthesis of 
Auranofin analogues in the search for improved activity and selectivity of the final complexes. Special atten-
tion has received those thiolate ligands derived from molecules with intrinsic antitumor activity or arising 
from biological relevant molecules. The use of thiolate ligands derived from DNA bases such as thiouracile, 
thiocytoxine, thioguanine, etc. may represent a good approach to obtain complexes with improved biologi-
cal activity, and with better transport and biodistribution in cancer cells. For this reason, we have reported 
several examples of gold complexes bearing this sort of molecules together with diverse ancillary ligands 
specially designed to improve properties such as the balance between lipophilicity and hydrophilicity as well 
as the cellular uptake.
As commented, the ancillary ligands bonded to gold are also important because they can provide the 
necessary stability in the biological media and can contribute to the final properties of the complexes. In 
this sense, aminophosphane is a family of ligands with the suitable characteristics to give access to metal 
complexes capable of forming hydrogen bonds, which is an important property in bioinorganic chemistry to 
produce more active compounds. With the main aim to develop biologically active compounds, a series of new 
gold(I) thiolate derivatives with different aminophosphanes as auxiliary ligands have been described. Thus, 
specifically 2-(diphenylphosphanylamino)pyridine (Ph2PNHpy) and 3-(diphenylphosphanylamino)-1,2,4-
triazole [Ph2PNH(Htz)] were first synthetized and, then, used to prepare several mononuclear gold(I) com-
pounds with thiolates starting from complexes 1 or 2 (Fig. 2) [27].
Complexes 3–6 were prepared by reaction between complex 1 and the respective thiol such as 2-mer-
captopyridine (for 3), 2-mercaptonicotinic acid (for 4), 2-thiouracil (for 5) or 2-thiocytosine (for 6) in the pres-
ence of sodium carbonate or triethylamine. In contrast, complexes 7–9 were synthesized starting from 2 and 
the corresponding thiol such as 2-mercaptopyridine (for 7), 2-thiocytosine (for 8) or 6-thioguanine (for 9) and 
trimethylamine.
The antitumor properties of complexes 1–9 were tested in vitro against two tumor human cell lines, HeLa 
(derived from cervical cancer) and MCF-7 (derived from breast cancer). Some of them showed excellent cyto-
toxic activity, especially derivatives with the PPh2NHPy aminophosphine ligand (3–6, IC50 values from 1.08 
to 1.34 μM) which showed excellent cytotoxic activity against MCF-7 cells, in comparison with complexes 7–9 
(IC50 values from 2.89 to 17.38 μM) (Table 1) [28].
Complexes 3–6 also showed interesting cytotoxic activities against the HeLa cell line, especially com-
plexes 3 and 4 (IC50 values of 1.70 and 0.91 μM, respectively), and complex 9 with a 0.34 μM for HeLa cell line. 
As control, we also investigated the antiproliferative effects of the metal-free ligands and chloride gold(I) 
derivatives 1 and 2 against the tumor cell line HeLa.
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Interestingly, the ligands used in this study did not show activity, with the exception of 6-thioguanine 
with strong antiproliferative effects (IC50 value of 1.24 μM), only slightly weaker than that found for the cor-
responding gold complex 9 (IC50 value of 0.34 μM, Table 1). This ligand has been previously used as an anti-
cancer agent and its biological activity has been previously investigated [29, 30]. Complex 1 bearing the 
aminophosphine and the chloro ligand also presented an IC50 value 8 times higher than the corresponding 
thiolate-complexes 3–6.
Additionally, the interactions of complexes 3, 5, 7 and 9 with thioredoxin reductase in HeLa cells were 
studied, with the main objective to shed light on the mechanisms of action of these compounds. As shown in 
Table 2 the complexes exhibited a high inhibition of thioredoxin reductase activity.
Other potential biological targets were also studied. Thus, interaction of these thiolate gold(I) complexes 
with calf thymus CT-DNA in Tris buffer was analyzed by electronic absorption titration. The values of intrinsic 
binding constants Kb of the complexes with CT-DNA ranges between 2 × 106 M−1 and 7 × 106 M−1 which indicates 
that complexes 1–9 had a strong binding affinity for CT-DNA. This result is surprising because in the specific 
case of complex 2, which did not show appreciable cytotoxic activity, it has a high intrinsic binding constant. 
Consequently, it is possible to propose, as in other gold(I) complexes reported in the literature, that the DNA 
is not the main target in spite of the binding interaction.
Table 1: IC50 (48 h, μM) of complexes 1–9 against HeLa and MCF-7 cell lines.
  HeLa   MCF-7
Cisplatin   10.50 ± 1.57a   19.04 ± 1.51a
Auranofin   5.99 ± 0.01   1.11 ± 0.30b
[AuCl(PPh2NHPy)] 1   25.04 ± 0.1  
[AuCl{PPh2NH(Htz)}] 2   >50  
3   1.70 ± 0.05   1.17 ± 0.06
4   0.91 ± 0.16   1.14 ± 0.08
5   3.29 ± 0.13   1.34 ± 0.07
6   3.25 ± 0.02   1.08 ± 0.13
7   4.34 ± 0.03   5.55 ± 0.34
8   18.96 ± 3.09   2.89 ± 1.07
9   0.34 ± 0.08   17.38 ± 1.22
aC. Marzano, V. Gandin, M. Pellei, D. Colavito, G. Papini, G. G. Lobbia, E. D. Giudice, M. Porchia, F. Tisato, C. Santini. J. Med. 





























































































Fig. 2: Gold(I) complexes bearing thiolate functionalized DNA-bases and aminophosphane ligands.
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These complexes also exhibit antibacterial activity against E. faecalis ATCC 25923, S. aureus ATCC 29213 
and E. coli TG1, which was evaluated by the Kirby–Bauer disk-diffusion test using the broad-spectrum anti-
biotic kanamicin as control (Table 3).
Based on the results shown in Table 3, it is possible to conclude that all complexes exhibited semiquanti-
tative antimicrobial activities similar to controls. In contrast, complexes 2–4 did not present activity against 
any of the microorganisms tested. Since many of these microorganisms are resistant to one or more antibi-
otics, there is an increasing interest in the development of alternative forms of bacterial varying between 5 
and 50 μm, interestingly these values suggest that some of our complexes could have potential applications 
in the impairment of the proliferation of E. faecalis and S. aureus. The activity of gold(I) complexes against 
the Gram-negative E. coli TG1 strain was lower, although complexes 6–8 still exhibit moderate bacteriostatic 
effect. This agrees with previous studies indicating that gold(I) complexes are, in general, more efficient 
against Gram-positive than against Gram-negative bacteria [31, 32]. The lower susceptibility could be attrib-
uted to the structural differences in the cell walls of those types of microorganisms. Although the analysis 
of the mechanism of action of these complexes in Gram-positive bacteria has not been performed, recent 
studies showed that the inhibition of thioredoxin reductase enzyme plays a very important role, especially in 
Auranofin itself which is a potent bacteria inhibitor [33]. This is in accordance with the higher inhibition also 
shown for cancer cells.
In a further study, we prepared ferrocenyl amide-phosphine ligands, since we envisioned their impor-
tance due to their ability to form hydrogen bonds and because of the presence of the ferrocenyl moiety, which 
has been used in medicine as an excellent scaffold to increase the biological activity of known commer-
cial drugs [34]. The ancillary ligands used were prepared by reaction of chlorocarbonylferrocene with two 
aminophoshines, H2NCH2CH2PPh2 (L1) or HN(CH2CH2PPh2)2 (L2). The treatment of the precursor complex 10 
bearing the monophosphine ligand L1  with various thiols such as 2-mercaptonicotic acid, 2-thiocytosine, 
2-thiouracil, and 6-mercaptopurine in the presence of K2CO3 produced the corresponding thiolate derivatives 
11–14 (see Scheme 1) [35].
Similarly, the reaction of the gold species bearing the diphosphine L2, [Au2Cl2{(PPh2CH2CH2)2-NCOFc}] 
(15), with thiols such as 2-thiocytosine or 2,3,4,6-tetra-6- acetyl-1-thiol-β-D-glucopyranosato in the presence 
of K2CO3 afforded complexes 16 or 17 (see Scheme 2).
Other gold(I) complexes with disubstituted ferrocenyl ligands represented in Fig. 3 were prepared for 
comparative purposes [36, 37]. The gold-chloride species further reacted with thiols such as 2-thiocytosine 
Table 2: Inhibitory effects on TrxR activity and antiproliferative effects for complexes 3, 5, 7 and 9 (IC50) in HeLa cells.
  % Inhibition of TrxR   IC50
3   77.4   1.70 ± 0.05
5   84.8   3.30 ± 0.13
7   54.8   4.30 ± 0.03
9   38.4   0.34 ± 0.08
Table 3: Antimicrobial activities evaluated as minimum inhibitory concentrations [μM] and minimum bactericidal 
concentrations [μM].
E. faecalis S. aureus E. coli
MIC MBC MIC MBC MIC MBC
1 10 30 >50 >50 _
5 5 50 5 >50 >100 >100
6 5 20 5 >50 30 100
7 5 >50 40 50 50 >100
8 15 >50 30 >50 50 >100
9 5 30 30 >50 _
Kanamacin 100 >100 >100 50 50
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(for 19), 2-thiouracil (for 21), and 2,3,4,6-tetra-6-acetyl-1-thiol-β-D-glucopyranosato (for 18 and 20) in the pres-
ence of K2CO3 to afford the thiolate gold species 18–21 (see Fig. 3).
The ferrocenyl-amide phosphine ligands and the gold complexes were tested for their antiproliferative 
effect against four tumor cell lines: the two murine cell lines NIH-3T3 (mouse embryonic fibroblasts) and 
PC-12 (pheochromocytoma of the rat adrenal medulla) and the two human cell lines A549 (adenocarcinomic 
human alveolar basal epithelial cells) and Hep-G2 (hepatocellular carcinoma).
All the ferrocenyl ligands used do not show any significant cytotoxic activity. However, the 























































Scheme 1: Synthesis of thiolate gold complexes 11–14 with the ligand PPh2CH2CH2NHCOFc. (i) 2-mercaptonicotinic acid + K2CO3, 





















































Scheme 2: Synthesis of gold complexes with the ligand (PPh2CH2CH2N)COFc. (i) 2 [AuCl(tht)], (ii) 2-thiocytosine + K2CO3, 
(iii) 2,3,4,6-tetra-6-acetyl-1-thiol-β-D-glucopyranosato + K2CO3.
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[AuCl(PPh2CH2CH2NHCOFc)] (10) in the murine cells, with a very low value for NIH-3T3 cells of 0.1 μM, and for 
the previously reported [Au2Cl2(μ-dppf)] which present IC50 values of 8.2 and 10.7 μM in the A549 and Hep-G2 
cell lines, respectively (Table 4).
The cytotoxic activity of all the thiolate gold derivatives 11–21 with the different amido-phosphine ligands 
have been measured (Table 4). The general trend is that excellent IC50 values are found in the murine cell lines 
NIH-3T3 and PC-12 and moderate to good values are found in the human cell lines A549 and Hep-G2. This activ-
ity is much better than the corresponding of the chloro-gold derivatives with the same ancillary ligand and also 
than those found for Auranofin and Cisplatin. The structure-reactivity relationship (SAR) in these complexes 
shows that the most active are the gold thiolate complexes with the monosubstituted amidophosphine ligand.
N-heterocyclic carbene (NHC) complexes are receiving much attention during the last years and are 
emerging as a promising class of metallodrugs [38]. The strong σ-donating ability of NHCs is comparable to 
that of phosphines and this provides with strongly bonded NHC ligands to gold. This fact, together with the 
ease functionalization of NHC ligands, makes them interesting scaffolds to develop new gold drugs [39].
As the substituents in the NHC ligands are very important to modulate the biological properties of the 
final gold complexes, acridine-based NHC ligands were chosen for this aim as the acridine is a chromophore 
itself and it is also well-known to be a good DNA intercalator [40]. First, the synthesis of the NHC gold-chlo-
ride and bis(carbene) species 22–29 were accomplished by a transmetallation reaction using silver oxide and 
several examples represented in Fig. 4 [41].
Additionally, the reaction of the NHC gold-chloride compounds with thiols produced the substitution of 
the chloride by the thiolate ligand (Scheme 3). We envisioned that the resulting thiolate acridine-NHC based 
Au(I) complexes containing thiopyridine or tetra-O-acetyl-1-thio-β-D-glucopyranoside could be promising 
candidates for biological studies (Table 5) [42].
All the complexes showed higher cytotoxicity towards MiaPaca2 cells than towards A549 cells. In general, 
Ag–NHC compounds seemed to be less cytotoxic than their Au–NHC analogs, following the same trend as pre-






















SR = TG (18), thiocytosine (19) SR = TG (20), thiouracil (21)
Fig. 3: Thiolate gold complexes prepared from disubstituted ferrocenyl ligands.
Table 4: IC50 (48 h, μM) of complexes 10–21 against NIH-3T3, PC-12, A549 and Hep-G2 cell lines.
Complex   NIH-3T3   PC-12   A549   Hep-G2
10   0.1   4.2   >100   68
11   0.4   2.1   12.6   7.8
12   0.8   2.4   95.1   >100
13   2.0   1.0   15.0   20.0
14   13.7     21.0   70.7
15   11.4     29.9   29.1
16   4.7     13.1   12.4
17   4.0     14.5   11.1
18   5.4     30.3   17.6
19   14.7     74.9   72.6
20   5.9     7.0   13.7
21   5.4     12.0   14.8
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(30–33) complexes, mimics of the well-known auranofín, exhibited the higher cytotoxic activity against both 
cell lines. Since complex 33 was found the most cytotoxic in the A549 cell line, its cell death mechanism was 
studied by a flow cytometry assay and the data suggested a programmed cell death mechanism (apoptotic 
mechanism).
Moreover, fluorescence cell microscopy was also used to know the cellular biodistribution of complex 27 
in A549 cells, among others (Fig. 5). Superimposition images revealed a clear lysosomal localization as also 
found for some dinuclear gold(I)-NHC carbenes by Baker and Berners-Price in 2006 [44] as well as for the 
antiarthritic gold(I) thiomalate (Myocrisin) [45], in contrast to the expected mitochondrial pattern for gold(I) 
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Scheme 3: Synthesis of the thiolate NHC gold complexes.
Table 5: IC50 (mM) of complexes 22–33 (DMSO) and cisplatin (H2O).
Complex A549 MiaPaca2 Complex A549 MiaPaca2
22 >50 44.4 ± 10.9 29 41.9 ± 4.2 20.0 ± 1.6
23 >50 51.9 ± 1.9 30 >50 28.4 ± 2.5
24 >50 22.8 ± 8.8 31 17.4 ± 4.5 7.5 ± 1.2
25 >50 38.3 ± 2.6 32 19.4 ± 2.3 2.8 ± 0.8
26 >50 40.6 ± 9.9 33 13.0 ± 3.6 3.4 ± 0.8
27 >50 14.3 ± 4.3 Cis-Pta 114.2 ± 9.1 76.5 ± 7.4
28 >50 6.9 ± 1.9
aIC50 value measured in the same experimental conditions as complexes 22–33, i.e. incubation for 24 h at 37 °C.
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The proofs also suggested that the complexes were not only located in the lysosomes, but also seem to 
have some nuclear permeability and accumulation in the nucleolus. Nuclear and nucleolar accumulation 
might be related to the affinity of Au(I) and Ag(I) to inhibit the TrxR1 and Trx1. Both enzymes are also present 
in the nuclear region especially in those stages of cellular stress promoted by the presence of a stress-induc-
ing drug [48].
In order to shed some light on the cause of this nuclear and nucleolar localization, preliminary studies on 
DNA interaction studies were performed for 22 and 33 as representative complexes of neutral Ag(I) and Au(I) 
complexes, respectively. Based on the changes observed in the electrophoretic mobility, we proposed that the 
most cytotoxic complex 33 showed some interaction character with DNA. In contrast, complex 22 did not. 
This finding pointed towards the nature of different metal–NHC fragment as the origin of the nuclear affinity, 
which contrasted with the initial idea that the acridine skeleton might act as DNA intercalator.
 Gold complexes with amino acids
Other interesting biological ligands are the amino acids, and beside the importance of this kind of molecules 
there are scarce examples of gold complexes with amino acid ligands and, consequently, their synthesis is 
still a challenge [49, 50]. We envisioned that if tumor cells over-express amino acid receptors, metal com-
plexes with amino acid ligands could be more selective towards damaged cells. In order to achieve a better 
Fig. 5: Images of A549 cells incubated with complex 27 and MitoTracker (left column), 27 and LysoTracker (right column) 27 for 
24 h (C = 1/2 of IC50). Excitation at 405 nm: emission from 27 (blue emission) and at 577 nm: emission from either the LysoTracker 
or MitoTracker (red emission). SI: superimposition image of complex and internal dye.
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stability of the final complexes, the amino acids were modified with different functional groups to allow a 
better coordination of the gold center to them.
With this idea in mind, the design of gold(I) complexes with thiolates ligands bearing amino acid moie-
ties seems to be an excellent approach to easily transport the gold complex to the biological target [51].
Therefore, we synthesized a series of gold(I) complexes starting from the nicotinic acid thiolate gold 
complex [Au(SpyCOOH)(PPh3)] 34, previously synthesized by Nomiya et al., who proved its anti bacterial 
activity [52], by coupling of the acid moiety with several amino acid esters giving rise to complexes 
35–40 (see Scheme 4) [53].
We further introduced different structural modifications taking complex 34 as a central core, in order to 
obtain new active derivatives and to establish a plausible structure–activity relationship (Fig. 6) [54].
The corresponding acid derivatives 41a–f were obtained by hydrolysis of starting amino acid esters 
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Scheme 4: Synthesis of complexes 35–40: (i) Glycine methyl ester, DIPEA, PyBOP; (ii) alanine methyl ester, DIPEA, PyBOP; (iii) 
valine methyl ester, DIPEA, PyBOP; (iv) phenylalanine methyl ester, DIPEA, PyBOP; (v) methionine methyl ester, DIPEA, PyBOP; 
(vi) proline methyl ester, DIPEA, PyBOP.
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We also performed the derivatization of amino acids 41a–f into the secondary amides 42a–f in a single 
step by coupling the amino acid derivatives with amines. Additionally, we synthesized complexes 43 and 
44, where the typical triphenylphosphine was substituted by diphenyl-2-pyridine phosphine and, finally, 
complex 45, where two gold metal centers are brought together within the same sulfur donor atom. Inter-
estingly, complex 45 could exhibit an increase in the cytotoxicity of the final complex and because it pre-
sents high lipophilicity that could help the complex to cross the cell membranes and/or accumulate in the 
mitochondria.
Other possible structural modifications were further introduced starting from acid 34, where changes 
were based on the coupled amino acid, or in the chirality to afford the molecules depicted in Scheme 5. We 
believed that these variations could influence the activity and/or the mechanism of action of the resulting 
gold complexes.
All these complexes were evaluated against three different human tumor cell lines: A549 (lung carci-
noma), Jurkat (T-cell leukaemia) and MiaPaca2 (pancreatic carcinoma). In general, the values obtained are 
considerably lower for these complexes in the most resistant cell lines, A549 or MiaPaca2, compared with 
cisplatin and present similar values in the Jurkat cell line. Importantly, the compounds showed some selec-
tivity for leukaemia cells against non-tumor cells (Jurkat vs. R69) but this difference was not seen in the case 
of solid tumors.
The family of ester complexes (35–40) displayed better cytotoxicity than the precursor complex 34 in all 
the cellular lines, with IC50 values ranging from 2.4 to 12.8 μM (Table 6). Particularly, the proline derivative 
40 was the most potent of this family of complexes, exhibiting excellent IC50 values in the three cancer lines, 
2.4 ± 0.04 in Jurkat, 9.4 ± 0.19 in MiaPaca2 and 7.4 ± 0.34 μM in A549. The two families of acids 41 and amides 
42 showed, in general, worse IC50 values than the corresponding esters.
The cytotoxicity values for the complexes with the structural modifications provided valuable informa-
tion about the structure-reactivity relationship (Table 6). Thus, the effect of changing the phosphine ligand 
in complexes 43 and 44 was not significant, probably because both phosphines have similar electronic and 
steric properties. However, the coordination of an additional AuPPh3+ fragment afforded a more active species 
45. This corroborates the observation that the cytotoxic activity of the complex is mainly attributed to the 
gold(I) atom, and the ligands bonded to gold are important as carriers to reach the biological target. Addition-
ally, the coupling of a different type of amino esters and the change in the quirality (complexes 46–52) do not 
seem to really improve the cytotoxicity (Table 6).
Considering all this data, the better cytotoxicity was achieved by the compounds functionalized as 
esters, with two gold(I) atoms per molecule and with conformationally-restricted or rigid amino acids, as in 
the case of proline (Table 6). Following this structure-activity relationship observed, a new complex was pre-
pared bearing the two gold centers and the functionalization with the proline ester (53) (Fig. 8). Compound 











Aa = Gly (41a), Ala (41b), Phe (41c), 










Aa = Gly (42a), Ala (42b), Phe (42c), 




























Fig. 7: Complexes prepared with the selected modifications.
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0.9 ± 0.07 μM (Table 6). This compound is the most potent among all complexes prepared in these series, and 
it is significantly more active than the precursors 40 and 45 in all the cell lines.
Additionally, the cell death mechanism was studied in both A549 and Jurkat cells, showing that complex 
40 induced non-apoptotic cell death in A549, while in Jurkat the cell death proceeded, both through apop-
tosis and necrosis. The generation of ROS was analyzed by flow cytometry after staining with 2-hydroxyeth-
idium, showing higher levels of these radicals in Jurkat cells than in A549 cells. The ROS levels produced kept 
good correlation with the loss of mitochondria membrane potential. The data suggested that the damage to 
the mitochondria could lead to an increase in the production of ROS that, in final instance, triggers cell death. 
Additionally, the inhibition of TrxR assay revealed that complex 40 at concentrations near to IC50 values are 
potent inhibitors of this enzyme, by decreasing the enzyme activity at least in a 50 %. The inhibition of this 
enzyme would prevent the removal of ROS and may be the reason for the high levels of ROS observed in the 
previous assay.
Following our previous works with the gold(I) complexes using the nicotinic acid thiolate with amino 
acid ligands [53], we decided to functionalized pyridine moieties with amino acids esters and to synthesize 
several gold(I) and gold(III) derivatives with two different phosphine fragments, PPh3 and PPh2py. The amino 
ester ligands bear then an aromatic amine as pyridine that coordinates metal fragments through the nitrogen 
atom, giving rise to all final metal complexes 55–63 (Scheme 6) [55].
After the synthesis, the in vitro cytotoxic activity of the ligands L3–L5 and the metal complexes 55–63 
was tested against four tumor human cell lines [A549 (human lung cancer), Hep-G2 (human liver cancer), 
HeLa (human cervix epithelial carcinoma), MCF-7 (breast cancer)] and one tumor mouse cell line [NIH-3T3 
(mouse fibroblast)] (Table 7). The resulting values were also compared with those obtained for cisplatin. 
Both, the ligands and the gold(III) complexes showed no cytotoxic activity. In contrast, the gold(I) complexes 



















































































Scheme 5: Synthesis of complexes 46–52: (i) HCl · H-Lys(Boc)-OMe, PyBOP, DIPEA, MeCN, (ii) TFA–DCM (1:1 v/v), (iii) HCl · H-Gly-
Pro-OMe, PyBOP, DIPEA, MeCN, (iv) HCl · H-Gly-OMe, PyBOP, DIPEA; LiOH, KHSO4; HNEt2, PyBOP, DIPEA; MeCN, (v) HCl-H-(D)-aa-
OMe, PyBOP, DIPEA, MeCN, (vi) LiOH, KHSO4.
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effective against HeLa (IC50 values range between 4.33 and 11.71 μM) and MCF-7 (IC50 values range between 
0.45 and 20.05 μM) cell lines, being 56 and 58, bearing the PPh2py ligand, and 59 with the PPh3 phosphine 
and the phenyl alanine methyl ester the most potent agents against MCF-7 with IC50 values of 0.65, 1.78 and 
0.45 μM, respectively.
In order to determine whether antiproliferation and cell death are associated with apoptosis, NIH-3T3 
cells were exposed to complex 56 (Annexin V +  FITC, PI) and analyzed by flow cytometry. These experiments 
showed that the mechanism by which this complex inhibits cell proliferation inducing cell death in NIH-3T3 
cells is mainly apoptotic.
Table 6: IC50 (24 h, μM) of complexes 34–53 against A549, MiaPaca, Jurkat, 293T, R69 cell lines.
Complex   A549  MiaPaca2  Jurkat  293T  R69
Cisplatin   105 ± 0.90  71 ± 0.80  7.4 ± 0.10  14.0 ± 0.20  65 ± 0.92
34   15.5 ± 0.92  9.2 ± 0.28  4.6 ± 0.08  4.6 ± 0.13  16 ± 0.64
35   11.5 ± 0.55  9.7 ± 0.22  3.8 ± 0.07  4.2 ± 0.08  8.6 ± 0.33
36   13.7 ± 0.71  11.0 ± 0.20  4.0 ± 0.07  2.7 ± 0.07  2.2 ± 0.08
37   10.9 ± 0.40  10.2 ± 0.25  3.3 ± 0.05  10.7 ± 0.31  19.0 ± 0.60
38   8.9 ± 0.36  12.3 ± 0.37  4.0 ± 0.08  5.5 ± 0.16  14.0 ± 0.59
39   8.2 ± 0.41  12.8 ± 0.32  4.1 ± 0.06  3.7 ± 0.07  9.6 ± 0.36
40   7.4 ± 0.34  9.4 ± 0.19  2.4 ± 0.04  10.0 ± 0.19  4.0 ± 0.13
41a   14.7 ± 0.88  8.2 ± 0.13  7.6 ± 0.11  35.2 ± 0.53  25.9 ± 1.04
41b   7.7 ± 0.22  10.7 ± 0.16  3.7 ± 0.06  12.8 ± 0.27  6.1 ± 0.18
41c   14.7 ± 0.20  12.3 ± 0.32  4.3 ± 0.08  11.3 ± 0.29  6.5 ± 0.25
41d   15.9 ± 0.50  11.5 ± 0.29  6.7 ± 0.13  65.5 ± 1.12  33.1 ± 1.13
41e   14.1 ± 0.55  14.5 ± 0.26  3.6 ± 0.06  49.3 ± 1.53  28.4 ± 1.16
41f   14.3 ± 0.61  11.6 ± 0.20  7.5 ± 0.07  3.0 ± 0.08  4.0 ± 0.11
42a   28.3 ± 1.02  27.2 ± 0.65  3.9 ± 0.06  14.4 ± 0.42  4.9 ± 0.16
42b   19.1 ± 0.67  8.1 ± 0.23  3.9 ± 0.07  8.1 ± 0.28  1.4 ± 0.04
42c   14.4 ± 0.60  12.5 ± 0.32  3.8 ± 0.06  7.6 ± 0.26  5.2 ± 0.15
42d   18.8 ± 0.71  14.1 ± 0.29  3.7 ± 0.06  14.6 ± 0.57  6.8 ± 0.23
42e   19.4 ± 0.62  15.2 ± 0.33  5.3 ± 0.11  13.6 ± 0.40  3.0 ± 0.09
42f   30.5 ± 0.82  19.2 ± 0.36  7.7 ± 0.15  5.8 ± 0.16  4.0 ± 0.16
43   nt  18.2 ± 0.51  5.2 ± 0.07  14.0 ± 0.28  4.9 ± 0.18
44   15.7 ± 0.66  17.4 ± 0.48  3.8 ± 0.04  12.0 ± 0.19  3.2 ± 0.13
45   6.9 ± 0.21  7.5 ± 0.19  3.3 ± 0.04  7.8 ± 0.19  1.8 ± 0.05
46   8.3 ± 0.39  13.1 ± 0.26  3.4 ± 0.06  3.5 ± 0.11  2.8 ± 0.08
47   32.5 ± 1.24  29.3 ± 0.70  36.5 ± 0.77  >25  10.4 ± 0.35
48   18.7 ± 0.64  22.5 ± 0.67  8.6 ± 0.14  17.9 ± 0.45  15.4 ± 0.60
49   33.5 ± 1.31  >50  nt  8.3 ± 0.19  1.9 ± 0.05
50   16.5 ± 0.92  17.1 ± 0.39  4.2 ± 0.05  7.7 ± 0.24  3.0 ± 0.08
51   18.3 ± 0.75  15.1 ± 0.27  3.6 ± 0.06  >25  1.2 ± 0.02
52   >50  >50  nt  >25  10.7 ± 0.29













Fig. 8: Structure of complex 53, synthesized following the best structure activity relationship.
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Continuing the studies with amino acids, and with the precedent that the proline amino acid ring pro-
vides higher activity to the compounds, probably because its more rigid conformation, we decided to center 
our research on the non-proteinogenic amino acid 4-mercaptoproline derivative 64 [56], which can be consid-
ered as a hybrid of proline and homocysteine. Therefore, we described the first synthesis of gold(I) bioconju-
gates with N-protected 4-mercaptoproline derivatives 65–69 (Fig. 9) [57].
Some structural modifications were performed on these compounds, such as the introduction of differ-














L3: PR3 = PPh3 (55), PPh2py (56)
L4: PR3 = PPh3 (57), PPh2py (58)




L3: L-valine methyl ester
L4: L-alanine methyl ester
L5: L-phenyl alanine methyl ester
54
Scheme 6: Synthesis of Au(I) complexes 55–60 and Au(III) complexes 61–63: (i) [Au(OTf)(PR3)] and (ii) AuCl3 · nH2O.
Table 7: IC50 (48 h, μM) of complexes 55–63 and ligands L3–L5 against A549, Hep-G2, NIH-3T3, HeLa and MCF-7 cell lines.
Complex A549 Hep-G2 NIH-3T3 HeLa MCF-7
L3 >50 >50 >50 >50 nt
L4 >50 >50 >50 >50 nt
L5 >50 >50 >50 >50 nt
55 24.56 ± 0.34 nt 4.76 ± 0.13 4.43 ± 1.43 6.04 ± 0.33
57 25.35 ± 0.40 10.50 ± 0.46 10.75 ± 0.43 11.71 ± 1.06 20.05 ± 0.34
59 >50 25.95 ± 0.16 3.71 ± 0.64 10.66 ± 0.33 0.45 ± 0.20
56 10.21 ± 0.60 10.18 ± 0.41 13.41 ± 1.37 4.33 ± 0.46 0.65 ± 0.34
58 25.22 ± 0.59 10.81 ± 0.78 10.31 ± 0.37 5.58 ± 0.86 1.78 ± 0.05
60 25.35 ± 0.44 10.85 ± 0.54 6.43 ± 1.55 6.93 ± 0.50 10.14 ± 0.69
61 >50 >50 >50 >50 nt
62 >50 >50 >50 >50 nt







































Fig. 9: Synthesis of gold complexes 65–69 with 4-mercaptoproline ester ligand derivatives.
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24 h) of the synthesized complexes was studied in vitro against three different human tumor cell lines [A549, 
Jurkat and MiaPaca2] and their structure-reactivity relationship (SAR) was also explored (Table 8).
Based on the results shown in Table 8, all gold complexes exhibited strong cytotoxicity with IC50 values 
in the μM range (<10 μM). In general, the Jurkat cell line was the most sensitive, and the A549 and MiaPaca2 
exhibited more resistance to our complexes. In all cases better activities were found in comparison with that 
achieved with cisplatin under the same conditions.
Analyzing the values of each complex, is possible to conclude that the cytotoxicity was mainly due to the 
gold atom. For instance, the presence of an additional Au(PPh3)+ fragment slightly improved the cytotoxicity 
of the new compound 69 in comparison with its mononuclear analog 66. On the other hand, we thought that 
the thiolate ligands could be involved in diverse exchange reactions with other biomolecules in the body, and 
they could determine the transport or biodistribution of the resulting complexes in the cells.
More recently, we have prepared thiophene bioconjugate complexes 71–73 of Ag(I) and Au(I) and Au(III) 
with tryptophan methyl ester 70, following the synthesis described in Scheme 7 [58].
Cytotoxicity studies towards several cancer lines such as A549, Hep-G2 or NIH-3T3 have been performed 
for the tryptophan derivatives 71–73 (Table 9). The thiophene bioconjugate 70 shows no activity whereas the 
gold (71 and 72) and silver (73) complexes exhibit moderate to good activities in two of the cell lines, with 
IC50 values going from 16 ± 0.97 to 56 ± 3.5 μM, and only the silver complex 73 is active in the A549 cell line 
(27 ± 1.3 μM).
The bioorganometallic chemistry of ferrocene has aroused a great interest due to its potential biological 
applications [34, 59]. Few examples of bioconjugates of ferrocene with amino acids [60–62], peptides [63–66], 
Table 8: IC50 (24 h) of complexes 65–69 (μM).
Complex   A549   MiaPaca2   Jurkat
65   1.8 ± 0.15   3.0 ± 0.19   0.8 ± 0.08
66   3.8 ± 0.37   6.1 ± 0.54   3.5 ± 0.32
67   >25   >25   9.3 ± 0.65
68   3.5 ± 0.29   2.3 ± 0.22   0.6 ± 0.08
69   1.9 ± 0.16   1.8 ± 0.17   0.5 ± 0.07




































Scheme 7: Synthesis of metal complexes 71–73 with 70. (i) [Au(acac)(PPh2py)], (ii) [Au(OTf)(PPh3)], (iii) [Ag(OTf)(PPh3)].
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proteins or DNA [67], among others, had been described and their potential applications in electrochemical 
sensor devices and immune assay reagents had been also explored [68, 69]. Ferrocene itself and its deriva-
tives have shown cytotoxic and antianemic activity in the area of medicinal chemistry [70]. The ferrocenyl 
core is also found in the structure of some biologically active compounds such as antibiotic [71], anticancer 
[72, 73], or malaria drugs [74, 75] and it has been demonstrated that its presence could result in an increase of 
the activity of the final molecules.
In this context, several bioconjugates of ferrocene (74–79) were prepared with biologically relevant 
ligands such as amino acid esters and related species. Their synthetic procedure entailed the reaction of 
chlorocarbonyl ferrocene with the corresponding amino acid ester (histidine methyl ester, tryptophan methyl 
ester, methionine methyl ester and lysine ethyl ester) or histamine or prolinamide in the presence of NEt3 
(Fig. 10) [76].
Gold(I) and gold(III) derivatives 80–86 were prepared with some of the synthesized ferrocene bioconju-
gates 76, 77 and 79 in order to test their biological activity (Fig. 11).
The ferrocene bioconjugates and the gold complexes 80–84 and 86 were tested for cytotoxicity against 
three tumor cell lines: two human cell lines, HeLa (derived from cervical cancer) and MCF-7 (derived from 
breast cancer), and one murine cell line, N1E-115 (derived from mouse sympathetic ganglion neurons of 
C-1300 mouse) (Table 10). The ferrocene bioconjugates did not exhibited significant antiproliferative activity 
in comparison with the gold complexes, which were more effective as cytotoxic agents.
These results displayed some interesting structure-reactivity relationships. In particular, the gold 
complex associated with methionine and PPh3, complex 84, showed a significant cytotoxicity in the two 
human cell lines. On the contrary, the gold(III) derivatives with pentafluorophenyl ligands showed larger IC50 
values in HeLa and MCF-7 cells whereas in NIE-115 cells presents a smaller value (30 μM).
In order to study the mechanism of action of our complexes related with their antiproliferative activity, 
their interaction with the DNA (calf thymus DNA) was explored. It was found that there were not changes in 
Table 9: IC50 (48 h, μM) of complexes 70–73 against A549, Hep-G2 and NIH-3T3 cell lines.
Complex   A549   Hep-G2   NIH-3T3
70   >100   >100   >100
71   >100   49 ± 2.5   18 ± 0.92
72   >100   49 ± 2.8   16 ± 0.97











































Fig. 10: Synthesis of starting ferrocenyl compounds 74–79.
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the specific viscosities upon the addition of compounds to a DNA solution, which confirmed that they do not 
act as DNA intercalators.
 Gold complexes with peptides
In spite of the great number of reported biologically active gold complexes, the works involving gold com-
plexes bearing peptides are still scarce. The use of peptides on drug discovery is one of the most promising 
fields in the development of new medicines [77, 78]. Similarly to amino acids, peptides are also useful carriers 
to deliver the metal into the biological target and could enable the complex to penetrate into the cell. In fact, 
the use of peptide bioconjugates with metal complexes for targeting of tumor cells has gained considerable 
attention in the last years [79–82].
A major problem for cancer chemotherapeutics is crossing the cell membrane, and a strategy to overcome 
this is to make use of the peptide-based delivery systems, which can transport small peptides and peptide-
like drugs to the cells. These peptide transporters have overexpressed receptors in some types of tumors, 
which could be a target for gold–peptide compounds, providing them with higher levels of internalization 
and subsequent selectivity [83]. In this context and with the aim of preparing more active and selective gold 
drugs, we proposed the formation of new gold(I) complexes with dipeptides.
We prepared a thiazolylalanine-containing peptide following the procedures depicted in Scheme 8 [84]. 



















PR3 = PPh3 (82), PPh2py (83)
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PR3 = PPh3 (80), PPh2py (81)
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Fig. 11: Gold complexes 80–86 with ferrocenyl-aminoacid ligands.
Table 10: IC50 values for complexes 80–84 and 86.
Compounds   HeLa   MCF-7   N1E-115
80   32 ± 1.8   15 ± 1.2   27 ± 2.2
81   22 ± 1.9   45 ± 1.7   26 ± 1.6
82   28 ± 1.6   52 ± 1.2   54 ± 2.3
83   29 ± 1.3   32 ± 2.5   <10 ± 2.2
84   18 ± 1.4   15 ± 1.8   29 ± 1.7
86   87 ± 2.0   88 ± 2.2   31 ± 2.4
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The iodide ligand can be substituted by a cysteine-containing dipeptide affording complex 90 (Scheme 9).
The cytotoxic activities of NSHC-gold(I) iodide 89 and bioconjugate 90 were assayed against three dif-
ferent human tumor cell lines: A549, Jurkat and MiaPaca2. Complex 89 displayed very good activity in vitro 
against all three tumor cell lines, with IC50 values of 0.4 ± 0.01, 16.6 ± 0.22 and 6.2 ± 0.1 μM, respectively. Sur-
prisingly, compound 90 bearing a coordinated dipeptide showed much lower activity in these cancer cells. 
This may be due to the higher lability of the Au–I bond compared with the Au–S bond, or may simply be a 
consequence of the higher lipophilicity of 89.
A family of cysteine-containing dipeptides 91b–96b was prepared starting from cystine by coupling dif-
ferent amino acids and using several orthogonal protections. The reaction with [AuCl(PPh3)] in the presence 
of K2CO3 gave the corresponding gold complexes 91c–96c (Scheme 10) [85]. In these molecules the gold center 
is coordinated directly to the dipeptide by the sulfur atom of the cysteine as thiolate.
In these gold(I) thiolate-dipeptide phosphine complexes different structural modifications such as 
change in the type of the amino protecting group (98), the type of phosphine (97), the number of gold frag-
ments coordinated to the sulfur center (100, 101), or the use of non-proteinogenic conformationally-restricted 
amino acid ester in the peptide (99), were introduced in order to evaluate their influence in the biological 
activity of the final complexes. The modified structures are depicted in Fig. 12.
The cytotoxic activity in vitro of these complexes has been evaluated against different tumor human cell 
lines (A549, MiaPaca2 and Jurkat) (Table 11). The complexes exhibited excellent cytotoxic activity with IC50 
values in the very low micromolar range, as low as 0.1 μM (Table 11). Interestingly, the best antipropiferative 
character was found when two AuPPh3+ fragments are coordinated to the Boc-Cys-Gly-OMe peptide, complex 




































































Scheme 9: Synthesis of complex 90.
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 Conclusions
The synthesis of antitumor gold complexes bearing relevant biomolecules has been accomplished by our 
research group. Gold compounds exhibit an extraordinary antiproliferative activity in several cancer cells 
and the ligands bonded to it are key for their transport through the bloodstream, to cross the cellular mem-
brane and to reach its biological targets. For these reasons, ligands derived from biological molecules present 
in the body such as thiol-functionalized DNA bases or sugars, amino acid and peptide derivatives are typ-
ically used. Several families of complexes were prepared with these molecules and using different ancil-
lary ligands such as aminophosphines, phosphines and N-heterocyclic carbene ligands. Excellent cytotoxic 
activity was found for most of the complexes in several cancer lines. In all the cases, the relation between 









































Gly  R = H  (91c), Ala  R = CH3  (92c), Val  R = CH(CH3)2 (93c), Phe R = CH2Ph  (94c)


























































Fig. 12: Structural modifications performed giving rise to 97–101.
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compounds bearing cysteine-containing dipeptides presented the highest activity in all the cancer cells. The 
structural modifications in which there were either a cyclic amino acid in the peptide or a second gold center, 
displayed the best structure-activity relationship. The gold complexes induced cellular death mainly through 
apoptosis or late apoptosis, although some necrosis process was also found. The studies performed showed 
that the mechanism of action could be derived from different processes. Inhibition of thioredoxin reductase, 
ROS production and in some cases interaction with DNA was observed, although other potential biological 
target could not be discarded.
 Acronyms




ATCC American Type Culture Collection
Boc tert-Butoxycarbonyl
Cis-Pt Cisplatin





E. coli Escherichia coli





HeLa Cervical cancer cell line (Henrietta Lacks)
Hep-G2 Hepatocellular carcinoma cells
Htz 1-H-1,2,4-Triazole
IBCF Isobutyl chloroformate
IC50 Half maximal inhibitory concentration
Jurkat T-cell leukemia
Kb Binding constant
Table 11: IC50 (μM) (24 h), with standard deviations, of complexes against A549, MiaPaca2 and Jurkat.
Complex   A549   MiaPaca2   Jurkat
91c   1.5 ± 0.2   2.0 ± 0.2   0.9 ± 0.1
92c   1.9 ± 0.1   1.9 ± 0.1   1.6 ± 0.1
93c   2.3 ± 0.1   3.0 ± 0.1   2.2 ± 0.1
94c   15.6 ± 0.11   5.4 ± 0.1   0.4 ± 0.1
95c   4.8 ± 0.1   1.8 ± 0.1   1.7 ± 0.1
96c   3.0 ± 0.1   0.7 ± 0.1   0.5 ± 0.1
97   5.0 ± 0.2   0.5 ± 0.1   0.8 ± 0.1
98   2.7 ± 0.1   1.5 ± 0.1   1.1 ± 0.1
99   2.1 ± 0.1   1.2 ± 0.1   1.5 ± 0.1
100   1.8 ± 0.1   0.1 ± 0.1   0.6 ± 0.1
101   3.5 ± 0.1   1.5 ± 0.1   0.8 ± 0.1
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MBC Minimum Bactericidal Concentration
MCF7 Breast cancer cell line (Michigan Cancer Foundation-7)
Me Methyl
Met Methionine
MiaPaca2 Human pancreatic cancer cell line
MIC Minimum Inhibitory Concentration
N1E-115 Mouse neuroblastoma cells
NHC N-heterocyclic carbene















ROS Reactive oxygen species
S. aureus Staphylococcus aureus
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